Dual PI3K/mTOR Inhibitors: Does p53 Modulate Response?
作者： Oleksandr Ekshyyan , Arunkumar Anandharaj , Cherie-Ann O. Nathan
DOI: 10.1158/1078-0432.CCR-13-1291
关键词:
摘要: Head and neck squamous cell carcinomas have multiple genetic alterations that can influence clinical response to treatment. It is important evaluate how distinct affect targeted agents identify a subset of patients who benefit from therapy, improving survival decreasing toxicity. Clin Cancer Res; 19(14); 3719–21. ©2013 AACR .
aacrjournals.org
sci-hub.se 参考文章(10)
S. J. Shuttleworth, F. A. Silva, A. R.L. Cecil, C. D. Tomassi, T. J. Hill, F. I. Raynaud, P. A. Clarke, P. Workman, Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors Current Medicinal Chemistry. ,vol. 18, pp. 2686- 2714 ,(2011) , 10.2174/092986711796011229
Seth A. Wander, Dekuang Zhao, Alexandra H. Besser, Feng Hong, Jianqin Wei, Tan A. Ince, Clara Milikowski, Nanette H. Bishopric, Andy J. Minn, Chad J. Creighton, Joyce M. Slingerland, PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy Breast Cancer Research and Treatment. ,vol. 138, pp. 369- 381 ,(2013) , 10.1007/S10549-012-2389-6
Wei Du, Yong Yi, Haibo Zhang, Johann Bergholz, Junfeng Wu, Haoqiang Ying, Yujun Zhang, Zhi-Xiong Jim Xiao, Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to Chemotherapy PLoS ONE. ,vol. 8, pp. e63179- ,(2013) , 10.1371/JOURNAL.PONE.0063179
Carolyn D. Britten, Lucy Chow, Dylan Conklin, Ondrej Kalous, Amrita Desai, Charles Ginther, Judy Dering, James Christensen, Robert Milham, Dennis J. Slamon, Richard S. Finn, Abstract LB-70:In vitroanti-cancer activity of PF-04691502, a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in a panel of human breast cancer cell lines Cancer Research. ,vol. 70, ,(2010) , 10.1158/1538-7445.AM10-LB-70
N. Stransky, A. M. Egloff, A. D. Tward, A. D. Kostic, K. Cibulskis, A. Sivachenko, G. V. Kryukov, M. S. Lawrence, C. Sougnez, A. McKenna, E. Shefler, A. H. Ramos, P. Stojanov, S. L. Carter, D. Voet, M. L. Cortes, D. Auclair, M. F. Berger, G. Saksena, C. Guiducci, R. C. Onofrio, M. Parkin, M. Romkes, J. L. Weissfeld, R. R. Seethala, L. Wang, C. Rangel-Escareno, J. C. Fernandez-Lopez, A. Hidalgo-Miranda, J. Melendez-Zajgla, W. Winckler, K. Ardlie, S. B. Gabriel, M. Meyerson, E. S. Lander, G. Getz, T. R. Golub, L. A. Garraway, J. R. Grandis, The Mutational Landscape of Head and Neck Squamous Cell Carcinoma Science. ,vol. 333, pp. 1157- 1160 ,(2011) , 10.1126/SCIENCE.1208130
Robert Millham, Brett Houk, Gary Borzillo, Josep Tabernero, Katherine Bell-McGuinn, Johanna Bendell, Julian Molina, Eunice Kwak, Geoffrey Shapiro, Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. mTOR / PI3-Kinase. ,vol. 10, ,(2011) , 10.1158/1535-7163.TARG-11-A167
Kathryn M. Kinross, Daniel V. Brown, Margarete Kleinschmidt, Susan Jackson, James Christensen, Carleen Cullinane, Rodney J. Hicks, Ricky W. Johnstone, Grant A. McArthur, In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer Molecular Cancer Therapeutics. ,vol. 10, pp. 1440- 1449 ,(2011) , 10.1158/1535-7163.MCT-11-0240
Jing Yuan, Pramod P. Mehta, Min-Jean Yin, Shaoxian Sun, Aihua Zou, Jeffrey Chen, Kristina Rafidi, Zheng Feng, Jeffrey Nickel, Jon Engebretsen, Jill Hallin, Alessandra Blasina, Eric Zhang, Leslie Nguyen, Minghao Sun, Peter K. Vogt, Aileen McHarg, Hengmiao Cheng, James G. Christensen, Julie L.C. Kan, Shubha Bagrodia, PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity Molecular Cancer Therapeutics. ,vol. 10, pp. 2189- 2199 ,(2011) , 10.1158/1535-7163.MCT-11-0185
Amanda Herzog, Yansong Bian, Robert Vander Broek, Bradford Hall, Jamie Coupar, Hui Cheng, Anastasia L. Sowers, John D. Cook, James B. Mitchell, Zhong Chen, Ashok B. Kulkarni, Carter Van Waes, PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer Clinical Cancer Research. ,vol. 19, pp. 3808- 3819 ,(2013) , 10.1158/1078-0432.CCR-12-2716
Hengmiao Cheng, Shubha Bagrodia, Simon Bailey, Martin Edwards, Jacqui Hoffman, Qiyue Hu, Robert Kania, Daniel R. Knighton, Matthew A. Marx, Sacha Ninkovic, Shaoxian Sun, Eric Zhang, Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design MedChemComm. ,vol. 1, pp. 139- 144 ,(2010) , 10.1039/C0MD00072H